Bayer brought together a legion of Latin American journalists for a press conference in Buenos Aires to outline its plans for the continent and detail its performance in each country.
Bayer brought together a legion of Latin American journalists for a press conference in Buenos Aires to outline its plans for the continent and detail its performance in each country.
Pharmabiz was present at the event, together with the major Latin American business news publishers for the event at the Park Hyatt hotel, in the Recoleta neighbourhood, hosted by Bayer Southern Cone CEO, the Mexican Eduardo Magallanes.
The German multinational’s spokesperson, Laura González Molero, president of Bayer Latin America, set out the company’s 2015 results, highlighting that Bayer was the fifth biggest drugsmaker in the region in terms of sales, according to IMS Health, and intended to continue to gain ground.
Brazil continues to be Bayer’s main market, followed by Mexico and the southern cone. Bayer does not believe Brazil’s economic downturn will seriously harm its performance.
Brazil continues to be Bayer’s main market, followed by Mexico and the southern cone (Argentina, Chile, Paraguay, Uruguay and Bolivia), but Bayer does not believe Brazil’s economic downturn will seriously harm its performance, González Molero told Pharmabiz.
She said: “We’re convinced that the Brazilian economy will find its course and that it’s simply a question of cycles.”
Liliana Lemme, medical director for Bayer in the southern cone, highlighted oncology, cardiology, ginocology, ophthalmology and hematology as the five main areas the company was focusing on, and said the company was putting its bets on the products Eylea for retinopathy, the intrauterine device Jaydess, the cardilological drug Xarelto, and the oncological drugs Xofigo, Stivarga, and Nexavar. The big news, however, was the cardiological drug Adempas, whose first batch was approved by Argentina’s regulatory body ANMAT last week.
Pharmabiz asked about the local status of the acquisition of MSD‘s OTC drugs – a deal that was agreed on an international level in 2014, but company’s spokespeople were unable to give details on the transaction.
[tribulant_slideshow gallery_id=»159″]
